MedicaidPrior AuthMedium impact
KMAP BULLETIN: Pharmaceutical Prior Authorization Updates – January 2026
Kansas Medicaid (KanCare)·KS · Oncology, Hematology, Psychiatry +2 more·Provider Bulletin
Effective date
Feb 1, 2026
We identified it
Jun 21, 2026
Summary
Kansas Medicaid (KMAP) is implementing new prior authorization requirements for 13 medications starting February 1, 2026 and March 21, 2026, while removing prior auth requirements for 2 medications on March 20, 2026. This affects prescription drug billing and requires updated prior authorization workflows.
Action Required
By February 1, 2026: Update prior authorization workflows to require PDL PA for 9 medications including Celecoxib (Vyscoxa™), Chlorzoxazone 250mg, Clonidine HCl (Javadin™), Desloratadine (Oral Solution), Insulin aspart-xjhz (Kirsty™), Losartan (Arbli™), Nabumetone (Relafen® DS), Oxaprozin (Coxanto™), and Ustekinumab-srlf (Imuldosa®). By March 20, 2026: Remove prior auth requirements for Clonidine HCl and Guanfacine HCl (Tenex®). By March 21, 2026: Implement Clinical PA requirements for 13 medications including Risdiplam (Evrysdi®), Zuranolone (Zurzuvae™), and others listed. Monitor KanCare MCO implementation dates as they may vary from KMAP bulletin dates.